Eli Lilly director Juan R. Luciano receives stock awards
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly & Co director Juan R. Luciano reported two direct common-stock award acquisitions on November 16, 2026: 11.1176 shares and 167.6364 shares, each reported at $1,431.67 per share. The 11.1176-share award was deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares following his separation from service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 11.1176 | $1,431.67 | $16K |
| Grant/Award | Common Stock | 167.6364 | $1,431.67 | $240K |
Footnotes (1)
- F1. At the election of the reporting person, the shares reported as acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
Key Figures
Key Terms
stock units financial
Lilly Directors' Deferral Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock awards did Eli Lilly (LLY) director Juan R. Luciano report?
When will the deferred Eli Lilly (LLY) award be settled?
AI-generated analysis. How Rhea-AI works. Not financial advice.